Abstract
Aim: Immunosuppressive drugs predispose the liver transplant recipient to reactivation of latent tuberculosis infections. Prophylactic therapies given to these patients are very important for prevention of reactivation. The aim of this study was to evaluate the prophylaxis of latent tuberculosis infections in liver transplant recipients.Methods: We designed a retrospective cohort study. We examined liver transplant recipients Between December 2014 and December 2017 with results of T Spot and prophylactic treatment.Results: Among 143 recipients, positive T Spot results were detected in 21 (14.7%) cases. Twenty one patients received Isoniazid prophylaxis and no reactivation of tuberculosis was detected during follow-up of 48 months.Conclusion: Isoniazid appears to be successful in prophylactic treatment of latent tuberculosis infection in liver transplant recipients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
